title: 131-I-metaiodobenzylguanidine treatment in patients with refractory advanced neuroblastoma.
abstract: Fourteen patients with refractory advanced neuroblastoma were treated with 131-I-metaiodobenzylguanidine (131-I-MIBG); all had evidence of progressive disease or recurrent disease following combination chemotherapy. One patient without gross evidence of disease, following surgical resection of recurrent neuroblastoma before therapy with 131-I-MIBG, remains healthy without regrowth of tumor 3.5 years later. Two other patients had minor responses, and one had a mixed response. Two patients remain alive 1,212 and 1,926 days following the initial 131-I-MIBG treatment; the remaining 12 patients died of progressive disease. Moderate myelosuppression was the most notable toxicity observed; mild nausea and vomiting and transient mild liver enzyme elevation were also encountered. Treatment with 131-I-MIBG produced antineoplastic activity in patients with neuroblastoma and was well tolerated. To evaluate dose escalation, alternative dosage schedules, and alternative MIBG-radioconjugates, additional trials of radiolabeled MIBG are indicated.
authors.affiliation: Department of Pediatrics, University of Michigan Medical School, Ann Arbor.
authors.forename: R J
authors.initials: RJ
authors.lastname: Hutchinson
authors.forename: J C
authors.initials: JC
authors.lastname: Sisson
authors.forename: B
authors.initials: B
authors.lastname: Shapiro
authors.forename: J S
authors.initials: JS
authors.lastname: Miser
authors.forename: D
authors.initials: D
authors.lastname: Normole
authors.forename: B L
authors.initials: BL
authors.lastname: Shulkin
authors.forename: I R
authors.initials: IR
authors.lastname: Francis
authors.forename: K
authors.initials: K
authors.lastname: Zasadny
authors.forename: J E
authors.initials: JE
authors.lastname: Carey
authors.forename: J W
authors.initials: JW
authors.lastname: Johnson
mesh_terms: D019797:3-Iodobenzylguanidine; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D007223:Infant; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007462:Iodobenzenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000473:pathology / Q000532:radiotherapy*; D016879:Salvage Therapy; D016019:Survival Analysis
chemical_list: D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine